AbbVie Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024 · Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease; Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
AbbVie to Acquire Cerevel Therapeutics in Transformative ... - News
Dec 6, 2023 · Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline; Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions; Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion
Cerevel is now part of AbbVie | AbbVie - Cerevel Therapeutics
Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders. Our scientists and oncologists strive to give patients improved treatment outcomes and a life beyond cancer by developing therapies that elevate the standards of care.
AbbVie Completes Acquisition of Cerevel Therapeutics - Yahoo Finance
Aug 1, 2024 · AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of the acquisition, Cerevel is now part of AbbVie.
AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer
5 days ago · AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of...
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
Jan 15, 2025 · The drug, picked up in AbbVie's $8.7 billion acquisition of Cerevel Therapeutics, failed to ease symptoms like hallucinations and delusions, leading the company to book a staggering $3.5 billion ...
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
Dec 7, 2023 · AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
AbbVie to Acquire Cerevel Therapeutics in Transformative …
Dec 6, 2023 · AbbVie will acquire all outstanding Cerevel common stock for $45.00 per share in cash. The proposed transaction is subject to customary closing conditions, including receipt of regulatory...
AbbVie Completes Acquisition of Cerevel Therapeutics
NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of the acquisition, Cerevel is now part of AbbVie.
AbbVie’s Cerevel deal hits an uncommon roadblock
Feb 20, 2024 · AbbVie’s multibillion-dollar bid to acquire Cerevel Therapeutics has hit an unusual snag that could prevent the deal from closing for months. The companies said that, on Feb. 16, they received a so-called second request from the Federal Trade Commission.